Arbor Pharmaceuticals, LLC, a U.S.-based specialty pharmaceutical company, announced today that Nymalize® (nimodipine) Oral Solution will now be available in a 10 mL (30 mg) unit dose cup. This new packaging option is designed specifically for patients whom require a dosage that is lower than the standard 20 mL (60 mg) dose. Nymalize provides accurate, consistent dosing in a ready-to-use form for subarachnoid hemorrhage (SAH) patients who cannot swallow capsules.
Nymalize is the first and only nimodipine oral solution indicated for the improvement of neurological outcome in adult patients with SAH1 and is available as a 473 mL (16 oz) bottle and as a carton of twelve individually wrapped 10 mL (30 mg) or 20 mL (60 mg) unit dose cups. Packaging of Nymalize meets the medication-storage provision of The Joint Commission on Accreditation of Healthcare. The product was approved by the U.S. Food and Drug Administration (FDA) in 2013 following a fast track designation and priority review.2
Patients with cirrhosis are at a higher risk of adverse reactions associated with SAH and should be administered a lower dose of nimodipine.1
“Arbor is committed to patient safety and recognized the need for additional ready-to-use options for specific patient populations. We are proud to add the Nymalize 10 mL unit dose cup to our growing portfolio of approved prescription products that can support the needs of patients,” said Ed Schutter, President and CEO of Arbor.
According to the State of Pharmacy Automation 2017 survey, most facilities are purchasing more than 70% of their medications in a bar code, unit dose format3 which demonstrates the need for more ready-to-use options from manufacturers.
Nymalize was developed by Arbor Pharmaceuticals. For more information, visit www.Nymalize.com.
About Subarachnoid Hemorrhage (SAH)
SAH is a serious, life-threatening condition that occurs in differing clinical contexts, the most common being head trauma, and refers to the leakage of blood into the subarachnoid space in the brain between the pial and arachnoid membranes. SAH familiarly refers to the spontaneous hemorrhages which occur with a ruptured cerebral aneurysm or arteriovenous malformation (AVM).
Nymalize is the first and only FDA-approved ready-to-use oral solution of nimodipine. This solution offers an effective alternative to capsule extraction for SAH patients who cannot swallow capsules. Nymalize is available in a 473mL (16 oz) bottle and 20mL (60mg), and 10mL (30mg) unit dose cups.
About Arbor Pharmaceuticals LLC
Arbor Pharmaceuticals, headquartered in Atlanta, Georgia, is a specialty pharmaceutical company currently focused on the cardiovascular, hospital and pediatric markets. The company has over 750 employees including 625 sales professionals promoting its products to physicians, hospitals, and pharmacists. Arbor currently markets 22 NDA or ANDA approved products with over 40 more in development. For more information regarding Arbor Pharmaceuticals or any of its products, visit www.arborpharma.com or send email inquiries to email@example.com.
Arbor Pharmaceuticals, LLC Contact
Spectrum Science Communications